News
Plexus Ventures Assists Celon Pharma to Out-License Certain Rights of Generic Advair® Diskus® to Lupin Limited for the U.S., Mexico, South Africa and Australia
Philadelphia, Pennsylvania - Plexus Ventures announces the successful completion of a recent out-licensing project on behalf of Celon Pharma. Additional details regarding the transaction, taken from Lupin Limited’s February 17, 2015 press release are included below:...
Plexus Ventures Completes Successful Divestment and Out-Licensing Projects
Philadelphia, Pennsylvania - Plexus Ventures announces the successful completion of two important partnering projects: ONE MORE SUCCESSFUL DIVESTMENT OF MATURE PRODUCTS Plexus provided professional services to Reckitt Benckiser (www.rb.com) in their divestment of a...
Plexus Ventures Assists Novartis with 10th Successful Product Divestment
Philadelphia, Pennsylvania - Plexus Ventures is pleased to announce the successful completion of its 10th product divestment for Novartis AG. Plexus provided professional services to Novartis Consumer Health, Inc. in the divestiture of U.S. commercial rights to...
Chika Yoshinaga, M.D. Joins Plexus Ventures as Senior Consultant
Philadelphia, PA - Plexus Ventures LLC, a leading global pharmaceutical business development consultancy, announced today that Dr. Chika Yoshinaga has joined the firm as Senior Consultant. Dr. Yoshinaga comes to Plexus Ventures with a breadth of experience in the...
Rottapharm | Madaus Acquires the Zyma® Brands; Plexus Ventures Facilitated the Deal
"Los Angeles, California -- Plexus Ventures is pleased to announce the successful completion of a recent divestment project. Plexus provided professional services to the seller in their divestment of the Zyma® Brands to Rottapharm | Madaus in 19 countries including...
Novartis Divests Optalidon to Omega Pharma
London, United Kingdom — Plexus Ventures is pleased to announce the conclusion of a successful divestment assignment for Novartis Consumer Health (Switzerland), for which Plexus Ventures acted as exclusive external advisor. Novartis recently sold the rights to...
Healthware Group and Plexus Ventures Form Alliance to Accelerate Partnerships Between Digital Therapeutics & Pharma
Milan and New York, 16/2/2021 – Healthware Group and Plexus Ventures have formed an alliance to structure deals for the pharmaceutical industry in the development and commercialization of DTx products. Given the increased attention and growth seen in the market, both...
Plexus Ventures Assists Glenmark Pharmaceuticals to Out-License Ryaltris™ Nasal Spray to Menarini for numerous markets throughout Europe
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Glenmark Pharmaceuticals. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal...
Events
BIO International Convention - Boston
June 16 – 19, 2025
Click to Schedule a Meeting
CHPI - Frankfurt
October 28 – 30, 2025
Click to Schedule a Meeting
Articles
Nucleic acid delivery: Are you developing what Big Pharma seeks?
Apr 11, 2023
How can we help you?
Plexus Ventures assists with M&A, divestments, licensing, strategic advice and consulting.
Subscribe to
Plexus News
Follow Us
Check out Plexus Ventures and other industry news shared daily.